oasis 3 semaglutide 1 trial The Rise of Oral Obesity Therapies: Semaglutide and Orforglipron Semaglutide as a GLP-1 Agonist:

By improving metabolic health, Semaglutide can reduce inflammation while helping regulate blood sugar and cholesterol

It's a life-saving medicine

Common side effects The most frequently reported side effects during the first four to eight weeks of semaglutide treatment include nausea (affecting 40-45% of users initially), constipation (approximately 24%), diarrhea (around 30%), abdominal bloating (roughly 20%), reduced appetite (this is actually the intended effect), fatigue (reported by 15-20% of users), and headaches (approximately 14%)

It is administered as a once-weekly subcutaneous injection, starting with a lower dose that is gradually increased over several weeks to a target dose of 2.4 mg, and should be used alongside a reduced-calorie diet and increased physical activity

For years, its role in weight management was less understood, but more recent research suggests GIP receptor activation may enhance the bodys sensitivity to GLP-1, improve fat metabolism, and further support appetite regulation

Individual responses vary based on sensitivity, dose level, and other factors